- Previous Close
0.9500 - Open
0.9700 - Bid 0.8974 x 100
- Ask 0.9566 x 100
- Day's Range
0.9000 - 1.0300 - 52 Week Range
0.9000 - 13.5900 - Volume
158,018 - Avg. Volume
294,259 - Market Cap (intraday)
32.768M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.75
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
www.fibrobiologics.comRecent News: FBLG
View More
Performance Overview: FBLG
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FBLG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FBLG
View MoreValuation Measures
Market Cap
34.59M
Enterprise Value
28.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
12.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-65.77%
Return on Equity (ttm)
-267.86%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.78M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
7.83M
Total Debt/Equity (mrq)
57.07%
Levered Free Cash Flow (ttm)
-128k